Riise Øystein Rolandsen, Laake Ida, Vestrheim Didrik, Flem Elmira, Moster Dag, Riise Bergsaker Marianne Adeleide, Storsæter Jann
From the *Department of Vaccine Preventable Diseases, and †Department of Infectious Disease Epidemiology and Modelling, Norwegian Institute of Public Health, Oslo, Norway; ‡Department of Global Public Health and Primary Care, University of Bergen, and §Department of Pediatrics, Haukeland University Hospital, Bergen, Norway; and ¶Department of Health Registries, Norwegian Institute of Public Health, Oslo, Norway.
Pediatr Infect Dis J. 2017 May;36(5):e151-e156. doi: 10.1097/INF.0000000000001545.
A few previous studies reported increased risk of pertussis in children with birth weight less than 2500 g. The risk of pertussis by degree of prematurity has not been determined in a cohort study. The vaccine effectiveness (VE) against reported pertussis in preterm infants is unknown.
Data were obtained from the Medical Birth Registry of Norway (1998-2010) and linked to other national registries. In total, 713,166 children were included in our study and followed until 2 years of age. Incidence rate ratios (IRRs) and confidence intervals (CIs) were estimated with Poisson regression.
We identified 999 reported cases of pertussis. We observed a higher rate of reported pertussis in preterm than in full-term infants, IRR = 1.65 (95% CI: 1.32-2.07). Compared to full-term infants, the risk of reported pertussis in infants born at gestational age (GA) 35-36, 32-34 and 23-27 weeks were higher [IRRs = 1.49 (95% CI: 1.11-2.01), 1.63 (95% CI: 1.06-2.51) and 4.49 (95% CI: 2.33-8.67), respectively]. Moreover, preterm infants had a higher rate of pertussis-related hospitalization than full-term infants [IRR = 1.99 (95% CI: 1.47-2.71)]. The VE against reported pertussis for the third dose was 88.8% (95% CI: 84.3-92.0) in full-term infants and 93.0% (95% CI: 85.8-96.5) in preterm infants.
In this cohort study, preterm infants including those born at GA 35 and 36 weeks had increased risk of reported pertussis. The VE was similar in preterm and full-term infants.
此前有几项研究报告称,出生体重低于2500克的儿童患百日咳的风险增加。在一项队列研究中,尚未确定早产程度与百日咳风险之间的关系。早产婴儿中针对报告的百日咳的疫苗效力(VE)尚不清楚。
数据来自挪威医疗出生登记处(1998 - 2010年),并与其他国家登记处相关联。我们的研究共纳入713,166名儿童,并随访至2岁。采用泊松回归估计发病率比(IRR)和置信区间(CI)。
我们确定了999例报告的百日咳病例。我们观察到,早产婴儿中报告的百日咳发病率高于足月婴儿,IRR = 1.65(95% CI:1.32 - 2.07)。与足月婴儿相比,孕龄(GA)35 - 36周、32 - 34周和23 - 27周出生的婴儿报告的百日咳风险更高[IRR分别为1.49(95% CI:1.11 - 2.01)、1.63(95% CI:1.06 - 2.51)和4.49(95% CI:2.33 - 8.67)]。此外,早产婴儿因百日咳住院的比例高于足月婴儿[IRR = 1.99(95% CI:1.47 - 2.71)]。第三剂疫苗针对报告的百日咳的效力在足月婴儿中为88.8%(95% CI:84.3 - 92.0),在早产婴儿中为93.0%(95% CI:85.8 - 96.5)。
在这项队列研究中,包括孕龄35周和36周出生的婴儿在内的早产婴儿报告的百日咳风险增加。早产婴儿和足月婴儿的疫苗效力相似。